Biosimilars in ophthalmology: “Is there a big change on the horizon?”
Ashish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; 3Department...
Guardado en:
Autores principales: | Sharma A, Reddy P, Kuppermann BD, Bandello F, Loewenstein A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/676b3cc895384c879856be8c32b38788 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immediate sequential bilateral intravitreal injections: an Indian perspective
por: Tripathy K
Publicado: (2017) -
Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar P, et al.
Publicado: (2021) -
Biosimilars: presumption of guilt
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011) -
Response to the Correct Usage of the Term “off-Label” in the Context of Corneal Cross-Linking [Response To Letter]
por: Motwani M
Publicado: (2021) -
Response to “A paradigm shift in eye banking: how new models are challenging the status quo by Moshirfar et al”
por: Moshirfar M
Publicado: (2019)